Hertab (Lapatinib) 250 mg

Approved indications:

• 🎗️ HER2-positive Advanced/Metastatic Breast Cancer: In combination with capecitabine, for patients who have received prior anthracycline, taxane, and trastuzumab therapy.
• HR+/HER2+ Metastatic Breast Cancer: In combination with letrozole, for postmenopausal women not candidates for chemotherapy.

Standard Dosing:

• With capecitabine: 1,250 mg (5 tablets) once daily, continuously.
• With letrozole: 1,500 mg (6 tablets) once daily, continuously.

⚠️ CRITICAL FOOD INTERACTION:

• 🚫 Take on an empty stomach. Food significantly increases drug absorption, raising the risk of toxicity.
• ⏰ Take at least 1 hour before or 1 hour after a meal, at the same time each day.
• Swallow tablets whole — do not crush, chew, or split.

💡 If a dose is missed, skip it — do not double the next dose.

• Severe hepatic impairment (dose reduction or discontinuation required).
• Known QTc prolongation or predisposition to arrhythmias.
• Pregnancy and breastfeeding.
• Concurrent use of strong CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampin) — use with caution.
• Known hypersensitivity to lapatinib or excipients.